AHEPA University Hospital, Department of Microbiology, Thessaloniki, Greece
School of Medicine, Aristotle University of Thessaloniki, Greece
New Microbiol. 2022 Jul;45(3):210-212.
We evaluated the in vitro activity of eravacycline and cefoperazone/sulbactam against 42 XDR and 58 PDR Acinetobacter baumannii isolates from blood and bronchoalveolar infections. The minimum and maximum MICs for eravacycline were 0.125 and 4 mg/L, respectively. The MIC50 was 2 mg/L and the MIC90 was 3 mg/L. The minimum and maximum MICs for cefoperazone/sulbactam were 24 and >256 mg/L, respectively. The MIC50 and MIC90 were both >256 mg/L. These novel agents were not adequate for the treatment of A. baumannii infections in our hospital and we recommend that mi- crobiology laboratories perform their own evaluations before including them in clinical practice.
我们评估了依拉环素和头孢哌酮/舒巴坦对 42 株来自血液和支气管肺泡感染的 XDR 和 58 株 PDR 鲍曼不动杆菌的体外活性。依拉环素的最低和最高 MIC 值分别为 0.125 和 4 mg/L。MIC50 为 2 mg/L，MIC90 为 3 mg/L。头孢哌酮/舒巴坦的最低和最高 MIC 值分别为 24 和 >256 mg/L。MIC50 和 MIC90 均>256 mg/L。这些新型药物不能充分治疗我院的鲍曼不动杆菌感染，我们建议微生物实验室在将其纳入临床实践之前自行评估。
